S

Sanofi

Global pharma company; vaccines and R&D

Brand Lead

Full-TimeUpdated on 10/23/2026Deadline 11/9/26
No salary listed
Expert
Bachelor's
Sydney NSW, Australia
In Person
Growth & MarketingBrand & Creative Marketing

About the job

Requirements
  • Extensive experience in brand management, with a proven track record in developing and executing successful brand strategies in the pharmaceutical or healthcare sector, particularly in a multi-country role.
  • Demonstrated capability of business planning and strategic function engagement.
  • Exposure to an international environment with deep knowledge and understanding of finance and Market Access.
  • Demonstrated experience in crafting and implementing comprehensive omni-channel strategies.
  • Experience integrating digital strategies within broader go-to-market plans, including product launches and market entry strategies.
  • Fluent English is required.
  • Ability to turn complex market data and insights into actionable strategies.
  • Ability to use data and insights to identify and prioritise opportunities.
  • Strong understanding of financial analysis and business case development.
  • Ability to develop innovative solutions and challenge conventional thinking.
  • Ability to lead, influence and collaborate with diverse stakeholders.
  • Ability to adapt to changing market conditions and solve complex challenges.
  • Strong understanding of healthcare professional and patient needs to develop relevant strategies and messaging.
Responsibilities
  • Lead integrated brand planning with a global and transversal approach, focusing on healthcare professional and patient needs, adapting to the competitive and environmental landscape, and using segmentation and targeted communication to achieve strategic brand objectives.
  • Monitor healthcare environments and competitive landscapes across markets, adapting strategies to maintain competitive advantage and comply with local regulations.
  • Lead market segmentation and identification of key targets, deploying tailored strategies and messages to engage each segment.
  • Craft compelling brand messages and identify key levers to influence target audiences, aligned with brand objectives and market opportunities.
  • Lead therapeutic area strategies throughout the product lifecycle, identifying opportunities for brand extension, rejuvenation and optimisation to maximise growth potential and profitability.
  • Develop and pitch business cases, using data and analytical capabilities to identify and prioritise growth opportunities.
  • Manage budgeting, forecasting and cost management to maximise revenue, profitability and market share at the country level.
  • Work with supply chain and operational teams to forecast and address product supply issues promptly, implementing solutions that minimise customer impact.
  • Develop and execute a detailed action plan aligned with brand goals and focus areas, ensuring effective resource allocation and timelines.
  • Follow corporate commitments and compliance guidelines.
  • Hold end-to-end accountability for brand performance across Australia and New Zealand, including in-line and new indications, covering brand strategy, segmentation and targeting, messaging and execution with digital innovation through global and cross-functional engagement.
Desired Qualifications
  • A bachelor's degree in pharmacy, biology, business administration, communication or a related field is preferred.
  • Familiarity with Australian Market Access experience is an advantage.
  • Established knowledge or experience in neurology is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...